Zevra Therapeutics (ZVRA) Long-Term Deferred Tax (2014 - 2019)

Zevra Therapeutics (ZVRA) has 6 years of Long-Term Deferred Tax data on file, last reported at $67.7 million in Q4 2019.

• Quarterly Long-Term Deferred Tax rose 32.1% year-over-year to $67.7 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $67.7 million (up 32.1% YoY) and the FY2019 annual result came in at $67.7 million, up 32.1% from the prior year.
• Long-Term Deferred Tax advanced to $67.7 million in Q4 2019, from $51.3 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $67.7 million in Q4 2019 to a low of $29.1 million in Q4 2015.
• A 5-year average of $46.0 million and a median of $45.0 million in 2016 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2015 — Long-Term Deferred Tax jumped 77.57% — and 2017, when it slipped 17.69%.
• Tracing ZVRA's Long-Term Deferred Tax over 5 years: stood at $29.1 million in 2015, then soared by 54.57% to $45.0 million in 2016, then decreased by 17.69% to $37.0 million in 2017, then surged by 38.46% to $51.3 million in 2018, then soared by 32.1% to $67.7 million in 2019.
• The last three Long-Term Deferred Tax figures came in at $67.7 million (Q4 2019), $51.3 million (Q4 2018), and $37.0 million (Q4 2017), per Business Quant data.